

***Fiscal Year 2024 Department of Defense Bone Marrow Failure Research Program (BMFRP)
Reference Table of Award Mechanisms and Submission Requirements***

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|--|---|---|--|--|
| <p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524BMFRPIDA</p> | <ul style="list-style-type: none"> • Early Career Investigators: Independent investigators at the level of Assistant Professor (or equivalent) who are less than 10 years from obtaining their first faculty appointment (or equivalent) by the application submission deadline. • Established Investigator: Independent investigators at or above the level of Associate Professor (or equivalent) or Assistant Professors (or equivalent) who are more than 10 years from obtaining their first faculty appointment (or equivalent) by the application submission deadline. | <ul style="list-style-type: none"> • Supports innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the vision to understand and cure bone marrow failure (BMF) diseases. • Proposed research should have a high probability of revealing new avenues of investigation. • Research project should include a well-formulated, testable hypothesis and a well-developed and articulated research approach. • Must address at least one of the FY24 BMFRP Focus Areas. • Personnel team should have strong background in BMF disease research. • May include relevant preliminary data. • Clinical trials are not allowed. • Hypothesis-driven correlative studies associated with clinical trials that meet the innovative intent of this award mechanism are encouraged. • Translational potential should be considered and described. • <i>Pre-application submission is required; application submission is by invitation only.</i> | <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$530,000 for direct costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. • The maximum period of performance is 3 years. | <p>Pre-Application (Preproposal): July 17, 2024 5:00 p.m. Eastern time</p> <p>Application: October 9, 2024 11:59 p.m. Eastern time</p> |

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|--|---|---|--|--|
| <p>Investigator-Initiated Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524BMFRPIIRA</p> | <p>Investigators at or above the level of Assistant Professor (or equivalent) by the application submission deadline.</p> | <ul style="list-style-type: none"> • Two Funding Levels: <ul style="list-style-type: none"> ○ Funding Level 1: Supports studies that further develop mature ideas, expand upon key discoveries, and have the potential to make significant advances in BMF research and patient care. Correlative studies associated with clinical trials are encouraged. Translational potential should be considered and described. ○ Funding Level 2: Supports Investigational New Drug (IND)-Enabling Efforts, which should be empirical in nature, product driven, and focused on the accumulation of data to support an IND application to the Food and Drug Administration. Applicants are required to identify at least one but no more than three lead therapy candidate(s), and transition plans should be considered and adequately described. • Emphasis on research approach and impact. • Personnel team should have strong background in BMF disease research. • Preliminary data required. • Clinical trials are not allowed. • Must address at least one of the FY24 BMFRP Focus Areas. • Partnering Principal Investigator (PI) Option: Allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application. • <i>Pre-application submission is required; application submission is by invitation only.</i> | <p>Funding Level 1:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$675,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. <p>Funding Level 2: IND-Enabling Efforts</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$850,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 2 years. | <p>Pre-Application (Preproposal): July 17, 2024 5:00 p.m. Eastern time</p> <p>Application: October 9, 2024 11:59 p.m. Eastern time</p> |